FDA approval and strong interim results have this small cap soaring 🦅

Be the best prepared trader on the Street!                                                                                                                                                                                                                                                                                                                                                                                                                 November 14, 2023 | [Read Online]( [Chat]( I [Deal](🎁 I [Bishop on X]( Good day, 360! Here are our top investing ideas today. These setups look primed! And we invite you to partake in some stellar [futures training](from Mr. Taylor Conway — with our compliments! FOCUS LIST🔎 THRX - Up over 35% in pre-market after announcing process to explore strategic alternatives, layoffs INVO - Up over 40% in pre after reporting earnings BCDA - Up over 100% in pre after receiving FDA approval for Phase 3 clinical trial SPOTLIGHT💡 New to trading? To options? Want to learn more? Then THIS deal is INSANE! 😵‍💫 Just [try it for ONE month]( and decide for yourself when you sign up for RB MarketMasters All-Access… You don’t just get RagingBull’s biggest chat room, that’s open pre-market to close every single day with over 500 active members… You ALSO get FULL ACCESS to ALL of “the Jeffs” services – including all trade plans, alerts and educational content available on demand! Take a peak 👀 and see [EVERYTHING]( this includes. And… new 360 Wall Street members get an additional 20% OFF when they sign up today using the coupon code: CHEERS Simply enter CHEERS in the box when you sign up [HERE]( & click “Apply” to instantly save 20% on your first month! HOTLIST🔥 THRX - Up over 35% in pre-market after announcing process to explore strategic alternatives, layoffs Theseus Pharmaceuticals (THRX) is a biopharmaceutical company that engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Yesterday, in the after-hours [THRX announced]( that it would explore strategic options and has cut its workforce by 72%. The company also stated that it had cash and cash equivalents and marketable securities of $225.4million. Based on yesterday’s close, according to Finviz THRX had a market cap of only $93.3million. The stock is trading up over 35% in the pre-market after the news release. The $2.93 area has acted as resistance in the after-hours and pre-market. Above it, targets to the upside are $3, and then the pre-market high at $3.15. Beyond that, $3.70, $4 and $5 come into play. Below $2.93, there is potential support at $2.86, $2.80, $2.70 and $2.52, with a gap to fill at $2.14. INVO - Up over 40% in pre after reporting earnings INVO Bioscience (INVO) is a commercial-stage fertility company that provides assisted reproductive technology solutions worldwide. In the after-hours yesterday, [the company reported]( Q3 EPS of -$0.70 beating estimates by $0.17 and up from -$4.20 a year prior. Sales came in at $0.97million up from $0.23million a year prior. The stock is trading up over 40% in pre-market post the earnings release. $2.25 was resistance in the pre-market and now becomes potential support. Above the first major target is the pre-market high at $2.41. Beyond that, $2.50, $3 and $4 come into play. Below $2.25, there is potential support at $2.08, $1.97, $1.90, $1.70, $1.60 and $1.50. BCDA - Up over 100% in pre after receiving FDA approval  BioCardia, Inc. (BCDA) is a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. This morning, [BCDA announced]( that it had received FDA approval to undertake its Phase 3 clinical trial of its CardiAMP Autologous Cell Therapy for treatment of patients with Ischemic heart failure. BCDA announced that the final data analyses will be reported in Q4 2024. In an interim analysis of available data to date results showed meaningful clinical improvements over controls, including a 59% relative risk reduction in heart death and a 54% relative risk reduction of Major Adverse Cardiovascular or Cerebrovascular events (MACCE). The stock traded up over 100% in pre-market after the news release. $0.81 was a support area in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.93, $1 and then the pre-market high at $1.05. Beyond that, $1.30, $1.50 and $2 come into play. Below $0.81 potential targets to the downside are $0.70, $0.60, $0.50 and then a gap fill at $0.3990. MARKET NEWS 📰 POLL: With earnings season well underway, the market : - [Is going to continue to make new highs into and post NVDA earnings]( - [Is overbought and due for a pull back]( P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America